GAITHERSBURG, Md., May 1, 2011 /PRNewswire/ -- MedImmune announced today it will present 11 abstracts at the Pediatric Academic Societies (PAS) Meeting at the Colorado Convention Center in Denver, CO, April 30 - May 3, 2011. These abstracts advance the body of existing data and knowledge surrounding influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued leadership in patient health.
MedImmune abstracts to be presented at PAS regarding influenza include:
- Factors Associated with Increased Vaccination in 2009 H1N1 School-Located Influenza Vaccination Programs. Ambrose CS, et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 468
- The Impact of School-Located Influenza Vaccination Programs on Student Absenteeism: A Review of the US Literature. Hull, HF, et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 473
- An Integrated, Multistudy Analysis of The Safety of Ann Arbor Strain Live Attenuated Influenza Vaccine in Children Aged 2-17 Years. Ambrose CS, et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 465
- Evidence of Homosubtypic But Not Heterosubtypic Immunity in Children After Wild-Type Influenza Illness. Ambrose CS, et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 469
- Factors Associated with Increased In-Office Influenza Vaccine Coverage and Two-Dose Compliance Among Practicing U.S. Pediatricians. Toback, SL, et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 467
- Maternal Outcomes in Pregnant Women Receiving Live Attenuated Influenza Vaccine. Toback, SL, et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 466
MedImmune abstracts to be presented at PAS regarding RSV include:
- RSV Prophylaxis: Chronologic Age, Number of Doses, and Timing of RSV Hospitalization. Griffin M., et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 558
- Safety Profile, Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccine in RSV/PIV3 Seronegative Children. Bernstein D., et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 458
- Burden of RSV Disease Among Infants 32-35 wGA in Outpatient Clinic Settings: The REPORT Study - Season One. Elhefni H., et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 556
- Hospitalizations Associated with Respiratory Syncytial Virus Among Infants 32-35 Weeks Gestational Age: Season One of the REPORT Study. Elhefni H., et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 557
- Distribution of Respiratory Syncytial Virus (RSV) Subtypes A and B Among Infants Presenting to the Emergency Department (ED) with Lower Respiratory Tract Infection (LRI) or Apnea. Jafri H., et al. Poster Session: May 1, 2011 Time: 4:15 - 7:30 PM, Exhibit Hall F, Board: 559
Additional information about the 2011 PAS conference can be found at
http://www.pas-meeting.org/2011Denver/default.asp
About MedImmune
MedImmune, the global biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.
SOURCE MedImmune
